PMC:7408073 / 70981-75554
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T424 | 598-604 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T425 | 1695-1709 | Body_part | denotes | left ventricle | http://purl.org/sig/ont/fma/fma7101 |
T426 | 1744-1750 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T427 | 2315-2322 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T428 | 2343-2359 | Body_part | denotes | pulmonary artery | http://purl.org/sig/ont/fma/fma66326 |
T429 | 2360-2379 | Body_part | denotes | smooth muscle cells | http://purl.org/sig/ont/fma/fma14072 |
T430 | 2374-2379 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
T431 | 4195-4199 | Body_part | denotes | face | http://purl.org/sig/ont/fma/fma24728 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T139 | 2343-2359 | Body_part | denotes | pulmonary artery | http://purl.obolibrary.org/obo/UBERON_0002012 |
T140 | 2353-2359 | Body_part | denotes | artery | http://purl.obolibrary.org/obo/UBERON_0001637 |
T141 | 4195-4199 | Body_part | denotes | face | http://purl.obolibrary.org/obo/UBERON_0001456 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
2562 | 1001-1005 | Gene | denotes | ACE2 | Gene:59272 |
2563 | 1185-1188 | Gene | denotes | ACE | Gene:59272 |
2564 | 1315-1319 | Gene | denotes | ACE2 | Gene:59272 |
2565 | 1554-1558 | Gene | denotes | ACE2 | Gene:59272 |
2566 | 1678-1682 | Gene | denotes | ACE2 | Gene:302668 |
2567 | 1768-1776 | Gene | denotes | Ang (1–7 | Gene:305843 |
2568 | 1957-1960 | Gene | denotes | ACE | Gene:302668 |
2569 | 2011-2015 | Gene | denotes | ACE2 | Gene:302668 |
2570 | 2026-2030 | Gene | denotes | MasR | Gene:116511 |
2571 | 2178-2182 | Gene | denotes | ACE2 | Gene:59272 |
2572 | 2310-2314 | Gene | denotes | ACE2 | Gene:59272 |
2573 | 2485-2488 | Gene | denotes | AT1 | Gene:185 |
2574 | 2498-2502 | Gene | denotes | ACE2 | Gene:59272 |
2575 | 2613-2617 | Gene | denotes | ACE2 | Gene:59272 |
2576 | 2716-2720 | Gene | denotes | ACE2 | Gene:59272 |
2577 | 4335-4339 | Gene | denotes | ACE2 | Gene:59272 |
2578 | 4351-4357 | Gene | denotes | Ang II | Gene:24179 |
2579 | 4399-4407 | Gene | denotes | Ang (1–9 | Gene:284 |
2580 | 4526-4530 | Gene | denotes | ACE2 | Gene:59272 |
2581 | 4531-4534 | Gene | denotes | ACE | Gene:59272 |
2582 | 4380-4388 | Gene | denotes | Ang (1–7 | Gene:284 |
2583 | 2016-2024 | Gene | denotes | Ang (1–7 | Gene:305843 |
2584 | 645-653 | Species | denotes | patients | Tax:9606 |
2585 | 1153-1161 | Species | denotes | patients | Tax:9606 |
2586 | 1453-1461 | Species | denotes | patients | Tax:9606 |
2587 | 1719-1723 | Species | denotes | rats | Tax:10116 |
2588 | 1860-1864 | Species | denotes | rats | Tax:10116 |
2589 | 1930-1934 | Species | denotes | rats | Tax:10116 |
2590 | 2076-2082 | Species | denotes | humans | Tax:9606 |
2591 | 2337-2342 | Species | denotes | human | Tax:9606 |
2592 | 2971-2979 | Species | denotes | patients | Tax:9606 |
2593 | 3172-3180 | Species | denotes | patients | Tax:9606 |
2594 | 3476-3484 | Species | denotes | patients | Tax:9606 |
2595 | 3532-3540 | Species | denotes | patients | Tax:9606 |
2596 | 3892-3900 | Species | denotes | patients | Tax:9606 |
2597 | 4031-4039 | Species | denotes | patients | Tax:9606 |
2598 | 4232-4240 | Species | denotes | patients | Tax:9606 |
2599 | 4292-4300 | Species | denotes | patients | Tax:9606 |
2600 | 2456-2462 | Gene | denotes | Ang II | Gene:24179 |
2601 | 451-458 | Chemical | denotes | calcium | MESH:D002118 |
2602 | 1494-1509 | Chemical | denotes | cholecalciferol | MESH:D002762 |
2603 | 1606-1614 | Chemical | denotes | losartan | MESH:D019808 |
2604 | 1633-1643 | Chemical | denotes | lisinopril | MESH:D017706 |
2605 | 3826-3834 | Chemical | denotes | losartan | MESH:D019808 |
2606 | 19-27 | Disease | denotes | COVID-19 | MESH:C000657245 |
2607 | 79-91 | Disease | denotes | hypertension | MESH:D006973 |
2608 | 93-101 | Disease | denotes | diabetes | MESH:D003920 |
2609 | 201-213 | Disease | denotes | hypertensive | MESH:D006973 |
2610 | 240-252 | Disease | denotes | hypertensive | MESH:D006973 |
2611 | 335-347 | Disease | denotes | hypertension | MESH:D006973 |
2612 | 907-919 | Disease | denotes | hypertension | MESH:D006973 |
2613 | 921-929 | Disease | denotes | diabetes | MESH:D003920 |
2614 | 931-943 | Disease | denotes | dyslipidemia | MESH:D050171 |
2615 | 1081-1093 | Disease | denotes | hypertensive | MESH:D006973 |
2616 | 1130-1138 | Disease | denotes | COVID-19 | MESH:C000657245 |
2617 | 1144-1152 | Disease | denotes | diabetic | MESH:D003920 |
2618 | 2226-2244 | Disease | denotes | hypoxic conditions | MESH:D000071069 |
2619 | 2635-2653 | Disease | denotes | hypoxic conditions | MESH:D000071069 |
2620 | 2662-2670 | Disease | denotes | COVID-19 | MESH:C000657245 |
2621 | 2985-2993 | Disease | denotes | COVID-19 | MESH:C000657245 |
2622 | 3088-3096 | Disease | denotes | COVID-19 | MESH:C000657245 |
2623 | 3208-3216 | Disease | denotes | COVID-19 | MESH:C000657245 |
2624 | 3275-3284 | Disease | denotes | mortality | MESH:D003643 |
2625 | 3436-3444 | Disease | denotes | COVID-19 | MESH:C000657245 |
2626 | 3656-3661 | Disease | denotes | death | MESH:D003643 |
2627 | 3854-3862 | Disease | denotes | COVID-19 | MESH:C000657245 |
2628 | 4009-4021 | Disease | denotes | hypertensive | MESH:D006973 |
2629 | 4022-4030 | Disease | denotes | diabetic | MESH:D003920 |
2630 | 4219-4231 | Disease | denotes | hypertensive | MESH:D006973 |
2631 | 4283-4291 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T348 | 19-27 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T349 | 79-91 | Disease | denotes | hypertension | http://purl.obolibrary.org/obo/MONDO_0005044 |
T350 | 93-101 | Disease | denotes | diabetes | http://purl.obolibrary.org/obo/MONDO_0005015 |
T351 | 335-347 | Disease | denotes | hypertension | http://purl.obolibrary.org/obo/MONDO_0005044 |
T352 | 907-919 | Disease | denotes | hypertension | http://purl.obolibrary.org/obo/MONDO_0005044 |
T353 | 921-929 | Disease | denotes | diabetes | http://purl.obolibrary.org/obo/MONDO_0005015 |
T354 | 931-943 | Disease | denotes | dyslipidemia | http://purl.obolibrary.org/obo/MONDO_0002525 |
T355 | 1130-1138 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T356 | 1619-1622 | Disease | denotes | ARB | http://purl.obolibrary.org/obo/MONDO_0012733 |
T357 | 1918-1921 | Disease | denotes | ARB | http://purl.obolibrary.org/obo/MONDO_0012733 |
T358 | 2267-2270 | Disease | denotes | ARB | http://purl.obolibrary.org/obo/MONDO_0012733 |
T359 | 2395-2398 | Disease | denotes | ARB | http://purl.obolibrary.org/obo/MONDO_0012733 |
T360 | 2485-2488 | Disease | denotes | AT1 | http://purl.obolibrary.org/obo/MONDO_0008840 |
T361 | 2662-2670 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T362 | 2812-2815 | Disease | denotes | ARB | http://purl.obolibrary.org/obo/MONDO_0012733 |
T363 | 2952-2955 | Disease | denotes | ARB | http://purl.obolibrary.org/obo/MONDO_0012733 |
T364 | 2985-2993 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T365 | 3011-3014 | Disease | denotes | ARB | http://purl.obolibrary.org/obo/MONDO_0012733 |
T366 | 3088-3096 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T367 | 3160-3163 | Disease | denotes | ARB | http://purl.obolibrary.org/obo/MONDO_0012733 |
T368 | 3208-3216 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T369 | 3226-3229 | Disease | denotes | ARB | http://purl.obolibrary.org/obo/MONDO_0012733 |
T370 | 3315-3318 | Disease | denotes | ARB | http://purl.obolibrary.org/obo/MONDO_0012733 |
T371 | 3436-3444 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T372 | 3494-3497 | Disease | denotes | ARB | http://purl.obolibrary.org/obo/MONDO_0012733 |
T373 | 3854-3862 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T374 | 4053-4056 | Disease | denotes | ARB | http://purl.obolibrary.org/obo/MONDO_0012733 |
T375 | 4123-4127 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T376 | 4195-4211 | Disease | denotes | face the disease | http://purl.obolibrary.org/obo/MONDO_0044987 |
T377 | 4283-4291 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T880 | 111-115 | http://purl.obolibrary.org/obo/UBERON_0003101 | denotes | male |
T881 | 111-115 | http://www.ebi.ac.uk/efo/EFO_0000970 | denotes | male |
T882 | 395-397 | http://purl.obolibrary.org/obo/CLO_0053794 | denotes | 41 |
T883 | 517-519 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
T884 | 586-594 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T885 | 598-604 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T886 | 664-665 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T887 | 694-695 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T888 | 783-787 | http://purl.obolibrary.org/obo/UBERON_0003101 | denotes | male |
T889 | 783-787 | http://www.ebi.ac.uk/efo/EFO_0000970 | denotes | male |
T890 | 865-873 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T891 | 1006-1014 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T892 | 1237-1238 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T893 | 1320-1328 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T894 | 1559-1567 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T895 | 1683-1691 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T896 | 1744-1750 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T897 | 1993-2003 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activation |
T898 | 2076-2082 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | humans |
T899 | 2301-2309 | http://purl.obolibrary.org/obo/UBERON_0000158 | denotes | membrane |
T900 | 2337-2342 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T901 | 2343-2359 | http://purl.obolibrary.org/obo/UBERON_0002012 | denotes | pulmonary artery |
T902 | 2343-2359 | http://www.ebi.ac.uk/efo/EFO_0001399 | denotes | pulmonary artery |
T903 | 2360-2379 | http://purl.obolibrary.org/obo/CL_0000192 | denotes | smooth muscle cells |
T904 | 2574-2575 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T905 | 2604-2612 | http://purl.obolibrary.org/obo/UBERON_0000158 | denotes | membrane |
T906 | 2701-2709 | http://purl.obolibrary.org/obo/UBERON_0000158 | denotes | membrane |
T907 | 3048-3049 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T908 | 3259-3260 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T909 | 3838-3839 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T910 | 4195-4199 | http://purl.obolibrary.org/obo/UBERON_0001456 | denotes | face |
T911 | 4242-4243 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T912 | 4474-4475 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T27957 | 111-115 | Chemical | denotes | male | http://purl.obolibrary.org/obo/CHEBI_30780 |
T23518 | 415-431 | Chemical | denotes | antihypertensive | http://purl.obolibrary.org/obo/CHEBI_35674 |
T31593 | 451-475 | Chemical | denotes | calcium channel blockers | http://purl.obolibrary.org/obo/CHEBI_38215 |
T57795 | 451-458 | Chemical | denotes | calcium | http://purl.obolibrary.org/obo/CHEBI_22984|http://purl.obolibrary.org/obo/CHEBI_29320 |
T11914 | 783-787 | Chemical | denotes | male | http://purl.obolibrary.org/obo/CHEBI_30780 |
T62420 | 1185-1199 | Chemical | denotes | ACE inhibitors | http://purl.obolibrary.org/obo/CHEBI_35457 |
T88754 | 1189-1199 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T52738 | 1201-1206 | Chemical | denotes | ACEIs | http://purl.obolibrary.org/obo/CHEBI_35457 |
T63223 | 1404-1416 | Chemical | denotes | antidiabetic | http://purl.obolibrary.org/obo/CHEBI_35526 |
T53003 | 1484-1489 | Chemical | denotes | ACEIs | http://purl.obolibrary.org/obo/CHEBI_35457 |
T85209 | 1606-1614 | Chemical | denotes | losartan | http://purl.obolibrary.org/obo/CHEBI_6541 |
T35617 | 1633-1643 | Chemical | denotes | lisinopril | http://purl.obolibrary.org/obo/CHEBI_43755 |
T72244 | 2315-2322 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T44056 | 2460-2462 | Chemical | denotes | II | http://purl.obolibrary.org/obo/CHEBI_74067 |
T66080 | 2538-2543 | Chemical | denotes | ACEIs | http://purl.obolibrary.org/obo/CHEBI_35457 |
T91113 | 2816-2832 | Chemical | denotes | antihypertensive | http://purl.obolibrary.org/obo/CHEBI_35674 |
T28525 | 3319-3341 | Chemical | denotes | antihypertensive drugs | http://purl.obolibrary.org/obo/CHEBI_35674 |
T296 | 3336-3341 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T83523 | 3498-3503 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T76894 | 3513-3518 | Chemical | denotes | ACEIs | http://purl.obolibrary.org/obo/CHEBI_35457 |
T83214 | 3553-3558 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T89355 | 3619-3624 | Chemical | denotes | ACEIs | http://purl.obolibrary.org/obo/CHEBI_35457 |
T57644 | 3826-3834 | Chemical | denotes | losartan | http://purl.obolibrary.org/obo/CHEBI_6541 |
T96201 | 3955-3960 | Chemical | denotes | ACEIs | http://purl.obolibrary.org/obo/CHEBI_35457 |
T89890 | 4139-4144 | Chemical | denotes | ACEIs | http://purl.obolibrary.org/obo/CHEBI_35457 |
T31128 | 4274-4279 | Chemical | denotes | ACEIs | http://purl.obolibrary.org/obo/CHEBI_35457 |
T305 | 4355-4357 | Chemical | denotes | II | http://purl.obolibrary.org/obo/CHEBI_74067 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T351 | 0-143 | Sentence | denotes | Severe symptoms of COVID-19 have been described to correlate with pre-existing hypertension, diabetes, age and male gender [1,2,3,4,5,6,7,8,9]. |
T352 | 144-521 | Sentence | denotes | It is not still clear whether it depends on constitutive hypertensive conditions and/or on anti-hypertensive treatments or on other age-related conditions, considering that the prevalence of hypertension in Chinese adults is ~ 23% and that only about 41% take prescribed antihypertensive medications, being calcium channel blockers the most commonly used (~ 50%) in China [11]. |
T353 | 522-760 | Sentence | denotes | To this regard, there is an interesting report describing sACE2 activity in plasma samples of Spanish healthy subjects and patients, in which a total of 2572 subjects from a multicenter study (NEFRONA project, 2009–2011) was studied [96]. |
T354 | 761-879 | Sentence | denotes | The report shows that male and advanced age were identified as independent predictors of enhanced sACE2 activity [96]. |
T355 | 880-1071 | Sentence | denotes | Furthermore, subjects with hypertension, diabetes, dyslipidemia, or plaques also had significantly increased circulating ACE2 activity when compared with those without these pathologies [96]. |
T356 | 1072-1287 | Sentence | denotes | Notably, hypertensive (the most frequent comorbidity with COVID-19) and diabetic patients are often treated with ACE inhibitors (ACEIs) and/or with ARBs, suggesting a possible positive correlation [135,136,137,138]. |
T357 | 1288-1573 | Sentence | denotes | Interestingly, circulating ACE2 activity is significantly increased in subjects on therapy with ARBs or taking oral antidiabetic agents as compared with non-treated patients, while treatment with ACEIs and cholecalciferol had no significant influence on circulating ACE2 activity [96]. |
T358 | 1574-1729 | Sentence | denotes | In line with this observations, losartan (an ARB), but not lisinopril (an ACEI), was able to upregulate ACE2 activity in left ventricle of Lewis rats [75]. |
T359 | 1730-2039 | Sentence | denotes | Nevertheless, plasma concentration of Ang (1–7) was significantly increased with both treatments when compared to vehicle-treated rats and it was significantly higher in ACEI-treated than ARB-treated rats [75], suggesting that ACE inhibition is able to induce an activation of the ACE2/Ang (1–7)/MasR pathway. |
T360 | 2040-2211 | Sentence | denotes | Although more evidence is needed in humans, the above observations suggest that ARBs should be precautionarily avoided to reduce possible ACE2-mediated viral consequences. |
T361 | 2212-2385 | Sentence | denotes | Indeed, under hypoxic conditions, either an ACEI or an ARB have been shown to upregulate membrane ACE2 protein expression on human pulmonary artery smooth muscle cells [58]. |
T362 | 2386-2537 | Sentence | denotes | ACEI and ARB have been shown to work by reducing the concentration of Ang II and by inhibiting its AT1-mediated ACE2 downregulation, respectively [58]. |
T363 | 2538-2793 | Sentence | denotes | ACEIs and ARBs might therefore play a role in the upregulation of membrane ACE2 expression under hypoxic conditions such as COVID-19, knowing that the increase of membrane bound ACE2 (before its shedding) will also increase the probability of viral entry. |
T364 | 2794-2896 | Sentence | denotes | Of note, ACEI and ARB antihypertensive medications are more commonly used in Europe/USA than in China. |
T365 | 2897-3121 | Sentence | denotes | Nevertheless, recent reports show that the use of ACEI/ARB medications in patients with COVID-19 is safe and ACEI/ARB exposure was not associated with a higher risk of having severe forms of COVID-19 [6,139,140,141,142,143]. |
T366 | 3122-3364 | Sentence | denotes | Moreover, some reports show that ACEI/ARB treated patients may even be protected from COVID-19 and ACEI/ARB exposure was associated with a lower risk of mortality compared to those on non-ACEI/ARB antihypertensive drugs [144,145,146,147,148]. |
T367 | 3365-3565 | Sentence | denotes | Among these reports, one indicates that the risk of severe symptoms of COVID-19 was significantly decreased in patients who took ARB drugs (but not ACEIs) compared to patients who took no drugs [144]. |
T368 | 3566-3792 | Sentence | denotes | Differently, another report suggests that the use of ACEIs (but not ARBs) reduced risk of death and/or critical disease [146], suggesting that some of these reports did not adjust for confounders and further analyses are need. |
T369 | 3793-3991 | Sentence | denotes | Nevertheless, clinical trials of losartan as a treatment for COVID-19, are actually underway among patients who have not previously been treated with ARBs and/or ACEIs (NCT04312009 and NCT04311177). |
T370 | 3992-4241 | Sentence | denotes | However, most of hypertensive/diabetic patients are ACEI- or ARB-“pretreated”, nevertheless they have an increased risk to develop SARS, therefore ACEIs and ARBs, if not detrimental, are not expected to face the disease in non-hypertensive patients. |
T371 | 4242-4573 | Sentence | denotes | A possible beneficial effect of ACEIs in COVID-19 patients could indirectly come by reducing ACE2 substrate, Ang II, and finally limiting Ang (1–7) [but not Ang (1–9)] production and its (detrimental) effects; however, this is only a hypothetical possibility since, in this case, the ACE2/ACE pathway might be even more unbalanced. |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T109 | 79-91 | Phenotype | denotes | hypertension | http://purl.obolibrary.org/obo/HP_0000822 |
T110 | 335-347 | Phenotype | denotes | hypertension | http://purl.obolibrary.org/obo/HP_0000822 |
T111 | 907-919 | Phenotype | denotes | hypertension | http://purl.obolibrary.org/obo/HP_0000822 |
T112 | 931-943 | Phenotype | denotes | dyslipidemia | http://purl.obolibrary.org/obo/HP_0003119 |
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32708755-32077115-20678898 | 124-125 | 32077115 | denotes | 1 |
32708755-32161940-20678899 | 126-127 | 32161940 | denotes | 2 |
32708755-32171076-20678900 | 128-129 | 32171076 | denotes | 3 |
32708755-32109013-20678901 | 132-133 | 32109013 | denotes | 5 |
32708755-32294485-20678902 | 134-135 | 32294485 | denotes | 6 |
32708755-32091533-20678903 | 136-137 | 32091533 | denotes | 7 |
32708755-31986264-20678904 | 138-139 | 31986264 | denotes | 8 |
32708755-32297671-20678905 | 140-141 | 32297671 | denotes | 9 |
32708755-29449338-20678906 | 517-519 | 29449338 | denotes | 11 |
32708755-25813276-20678907 | 756-758 | 25813276 | denotes | 96 |
32708755-25813276-20678908 | 875-877 | 25813276 | denotes | 96 |
32708755-25813276-20678909 | 1067-1069 | 25813276 | denotes | 96 |
32708755-32171062-20678910 | 1270-1273 | 32171062 | denotes | 135 |
32708755-32222168-20678911 | 1274-1277 | 32222168 | denotes | 136 |
32708755-32222169-20678912 | 1278-1281 | 32222169 | denotes | 137 |
32708755-32665962-20678913 | 1282-1285 | 32665962 | denotes | 138 |
32708755-25813276-20678914 | 1569-1571 | 25813276 | denotes | 96 |
32708755-15897343-20678915 | 1725-1727 | 15897343 | denotes | 75 |
32708755-15897343-20678916 | 1936-1938 | 15897343 | denotes | 75 |
32708755-32294485-20678917 | 3098-3099 | 32294485 | denotes | 6 |
32708755-32356628-20678918 | 3116-3119 | 32356628 | denotes | 143 |
32708755-32228222-20678919 | 3347-3350 | 32228222 | denotes | 145 |
32708755-32474043-20678920 | 3351-3354 | 32474043 | denotes | 146 |
32708755-32422341-20678921 | 3355-3358 | 32422341 | denotes | 147 |
32708755-32302265-20678922 | 3359-3362 | 32302265 | denotes | 148 |
32708755-32474043-20678923 | 3687-3690 | 32474043 | denotes | 146 |